TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
ASMB

Assembly Biosciences Inc

Healthcare · Biotechnology

22.50$ -1.9% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Assembly Biosciences Inc (ASMB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 331 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ASMB
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
109 98 134 123 112 169 156 142 283 268 259 242 223 340 313 295 306 283 279 262 249 191 163 143 122 102 83 67 52 137 120 115 100 119 99 81 240 258 236 331
59 54 92 78 69 123 113 98 240 223 201 183 165 283 257 235 246 224 222 206 188 154 131 124 115 97 80 64 50 134 117 113 98 116 96 77 237 255 233 328
24 29 71 39 27 82 67 54 120 41 29 34 25 47 42 97 58 59 78 60 71 46 51 43 55 52 43 22 27 20 19 19 28 38 23 24 23 58 31 32
59 53 91 76 66 120 109 93 234 218 194 174 157 274 249 227 238 216 215 199 181 147 123 117 109 92 73 60 46 130 113 109 95 112 91 75 233 248 227 320
– – – 1.1 1.4 2.3 2.3 2.1 2.6 2.4 3.0 2.9 2.9 3.4 3.1 3.3 3.6 1.2 0.2 0.3 0.8 0.3 0.5 0.5 1.2 0.9 0.7 0.3 0.1 0.0 0.0 0.4 0.0 0.4 0.4 0.3 0.9 1.0 0.5 0.8
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – 0.0 – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 0.0 0.0 0.0 – – -0.1 0.0 – – – – – – – – – –
0.1 0.2 0.2 0.1 0.6 0.9 0.7 0.6 0.5 0.6 2.1 2.0 1.9 1.8 1.8 2.1 1.9 1.6 1.5 8.8 1.2 7.2 6.3 0.9 4.8 0.7 0.6 2.2 – – – – – – – – – – – –
13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 0.0 – – – – – – – – – – – – – – – – – –
29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 29 – – – – – – – – – – – – – – – – – – –
19 18 66 66 65 56 54 53 54 57 69 67 67 67 62 28 36 43 32 30 24 22 16 19 19 19 13 12 9.9 96 87 81 74 86 72 63 57 51 37 25
7.5 7.1 11 12 12 13 12 13 15 18 25 20 21 24 21 17 17 24 14 14 15 16 11 15 15 16 10.0 8.8 7.1 39 39 41 42 48 47 47 53 49 35 23
– – – – – – – – – – 2.7 2.9 3.2 3.2 3.3 3.3 3.3 3.4 2.9 3.0 3.1 3.2 3.2 3.3 3.4 3.4 2.5 1.7 0.9 1.2 1.1 1.3 1.3 0.5 0.5 0.5 0.5 0.6 0.6 0.6
3.8 2.4 1.9 0.7 0.9 2.1 2.4 2.5 3.0 3.7 2.4 3.4 2.7 1.7 2.1 3.6 1.6 4.6 3.6 2.9 2.6 2.7 1.4 2.5 1.9 2.5 1.2 0.9 0.8 0.5 0.7 0.8 1.3 0.6 0.9 0.7 1.7 1.2 1.1 1.2
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 11 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
90 80 68 57 47 113 102 89 229 211 190 175 156 273 252 267 271 241 247 232 225 169 147 124 102 83 70 55 42 41 33 35 26 33 27 18 183 207 199 306
-197 -208 -222 -236 -248 -251 -267 -294 -316 -342 -369 -387 -412 -439 -466 -459 -462 -502 -529 -552 -571 -631 -655 -679 -702 -725 -743 -760 -775 -786 -795 -806 -816 -826 -835 -845 -854 -832 -841 -845
1.7 1.7 1.7 1.7 1.7 2.0 2.0 2.1 2.5 2.6 2.6 2.6 2.6 3.5 3.5 3.7 3.6 4.0 4.0 4.3 4.6 4.6 4.8 4.8 4.8 4.1 4.3 4.4 4.4 5.5 5.5 5.6 6.4 6.6 7.5 7.7 7.7 11 17 19

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?